Harmony Biosciences Holdings Inc

Harmony Biosciences wins FDA approval for WAKIX in pediatric narcolepsy, boosting its market and offering new hope for young patients.

Explore Harmony Biosciences’ strategy and market outlook—discussed at the JP Morgan Healthcare Conference—to gauge its sleep‑wake therapeutics upside and analyst sentiment for investors.

Harmony Biosciences Holdings, Inc. is a leading healthcare company specializing in the development of innovative treatments for neurologic disorders related to sleep-wake state instability, with a strong market presence and commitment to transparenc…

Harmony Biosciences Holdings Inc. reported strong Q1 2025 financials, exceeding market expectations with $184.7 million in revenue and $0.78 EPS, solidifying its position in the pharmaceutical sector.